Online inquiry

IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11896MR)

This product GTTS-WQ11896MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CCR2 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001123041.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 729230
UniProt ID P41597
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11896MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11981MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-005
GTTS-WQ4368MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ10105MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ6409MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ12429MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ3110MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ6626MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ11851MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW